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Abstract: Overactive bladder (OAB) is a difﬁ  cult condition to live with and is very costly to 
the community. OAB affects 16% of the adult population and rises with increasing age. We 
describe the necessary steps in evaluation and behavioral therapy prior to initiating medical 
therapy. There are several medications that have been used for the treatment of patients who 
suffer from OAB. This manuscript discusses the popular agents used for OAB, with a focus on 
the recent clinical trials on darifenacin.
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Introduction
Overactive bladder (OAB) is a problem characterized by urgency; a sudden desire 
to urinate that cannot be postponed. According to the International Continence Soci-
ety (ICS) “urgency, with or without urge incontinence, usually with frequency and 
nocturia, can be described as the overactive bladder syndrome, urge syndrome, or 
urgency-frequency syndrome. These terms can be used if there is no proven infection 
or obvious pathology.”(Wein and Rovner 2002). It can be associated with frequency 
and nocturia, and it may occur with urinary incontinence. OAB affects approximately 
16% of the adult population in the US and the prevalence increases with age (Wein 
and Rovner 2002; Beneton and De Parisot 2003).
OAB costs an estimated US$12 billion annually in the US, with US$9 billion 
incurred in the community (Basra and Kelleber 2007). The estimate includes both the 
direct costs of care, protective undergarments, and treatment as well as consequential 
costs, such as those resulting from urinary tract infections and falls due to urgency 
to get to the bathroom. There are intangible costs such as pain, suffering, and poor 
quality of life. The negative impacts on health, the ability to function, and quality of 
life have been well-documented. The elderly with OAB and subsequent incontinence 
are more likely to be admitted to nursing homes. Thom et al (1997) found at least a 
2-fold increase in risk of admission to a nursing facility for patients with incontinence. 
Urinary incontinence can lead to anxiety, negative self-image, and isolation (Basra and 
Kelleber 2007). OAB places individuals at risk for other forms of morbidity. Problems 
associated with OAB include skin ulceration and urinary tract infections. Nocturia, 
waking up more than one time per night to void, is common with OAB and is among 
the most bothersome of lower urinary tract symptoms (Ohelke 2005). In addition to 
sleep interruption and resulting fatigue, patients with nocturia may be more likely to 
suffer from falls and fractures, which are associated with high morbidity in elderly 
patients (33% of patients do not survive beyond 1 year after a hip fracture) (Reeves 
et al 2006).
The immediate consequences and co-morbidities of OAB can have a negative inﬂ  u-
ence on quality of life, particularly among the elderly. The effect of OAB becomes Clinical Interventions in Aging 2008:3(3) 504
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clearer with the National Overactive Bladder Evaluation 
(NOBLE) study (Coyne et al 2004). In this study, OAB 
was associated with much lower quality-of-life scores, 
higher scores on depression, and poorer sleep quality when 
compared to patient controls (Coyne et al 2004). Although 
OAB increases with age, it should not be considered a normal 
consequence of aging by patients or physicians. By using 
a systematic approach to diagnosing and evaluating OAB 
followed by instituting appropriate therapy, care providers 
can improve the health and quality of life of older patients 
with OAB.
Normal bladder physiology
Bladder function represents an interplay between the urinary 
tract and the nervous system. There are two main phases, 
ﬁ  lling and emptying. The normal bladder stores urine at a 
low pressure that remains lower than urethral resistance. 
Micturition is hallmarked by a decrease in urethral resis-
tance and contractions of the detrusor muscle with resultant 
emptying.
There is a complex interplay of neurotransmitters and 
receptors leading to normal bladder function. Acetylcholine, 
by acting on muscarinic receptors within the bladder, is the 
primary neurotransmitter in bladder contraction (Yamanishi 
et al 2001). Contraction occurs as a result of increased para-
sympathetic outﬂ  ow and relaxation of sympathetic inhibition. 
There are 5 known muscarinic subtypes (M1 to M5) that 
are distributed throughout the human body (Table 1). The 
muscarinic receptor subtypes are located in smooth muscle 
(bladder), exocrine glands, the nervous system, and the 
heart. M2 receptors are the predominant subtype within the 
healthy detrusor muscle; activation of M2 receptors inhibits 
sympathetically mediated detrusor relaxation. M2 receptors 
are also located in the heart and central nervous system 
(CNS). M3 receptors are responsible for detrusor smooth 
muscle contraction and also have an exocrine function in the 
salivary glands (Pontari et al 2004). The muscarinic receptor 
antagonists used to treat OAB may affect these receptors to 
varying levels. The use of muscarinic receptor antagonists 
is associated with a spectrum of outcomes in both efﬁ  cacy 
and side-effect proﬁ  le.
Evaluating patients 
with overactive bladder
Patients with uncomplicated OAB can be managed by the 
primary care physician. The ﬁ  rst step is to screen for a his-
tory of frequency, urgency, and incontinence. Unfortunately, 
many patients with OAB do not seek treatment because of 
embarrassment, the misconception that the problem is an 
inevitable consequence of aging, or that treatment options 
are limited. The history should focus on relevant medical, 
neurologic, and genitourinary symptoms that may lead to or 
worsen the symptoms of OAB. Neurologic conditions such 
as Alzheimer’s or Parkinson’s disease may affect cortical 
inhibitory function, which can cause or contribute to OAB 
(Stevens et al 2007). Conditions that affect the spinal cord 
(multiple sclerosis, disc herniation) may also disrupt normal 
micturition reﬂ  exes, resulting in OAB. Factors that affect 
the genitalia or the lower urinary tract, eg, bladder cancer, 
atrophic vaginitis, yeast infections, and cystitis, may lead to 
symptoms similar to OAB. When dealing with symptoms 
of OAB, it is imperative to identify causes that are easily 
reversed and appropriately manage these patients. In addition 
to a thorough history, assessment of ﬂ  uid intake, voiding pat-
terns, and real-time symptoms should be reviewed with the 
aid of a patient-completed voiding diary. In this exercise the 
patient logs intake of ﬂ  uid, number of times voided, amount 
voided, and episodes of incontinence for at least one full 
day. It is important to asses for medical conditions that lead 
to increased production of urine during sleep, eg, diabetes 
mellitus, diabetes insipidus, sleep apnea, or congestive heart 
failure. Nocturnal polyuria is calculated as  35% of daily 
urine production occurring during the sleep hours.
All medications should be reviewed for those that may 
affect urinary function, output, and so on. Diuretics, by 
increasing urinary output, clearly increase urinary frequency. 
Occasionally patients report night-time administration, a 
reversible cause of nocturnal polyuria. Various medications, 
including anticholinergics, narcotics, and calcium channel 
blockers, may decrease bladder contractility, leading to 
inability to completely empty the bladder and more frequent 
voiding. In addition, the use of sedatives may lead to deceased 
mobility and inability to get to the bathroom in time, leading 
to incontinence.
Physical examination should include the abdominal, 
genitourinary, rectal, and neurologic systems. It is important 
during the abdominal examination to make sure the bladder 
Table 1 Muscarinic receptors distribution (after Yamanishi et al 2001)
Muscarinic receptor Distribution
M1 Brain (cortex, hippocampus), glands, 
sympathetic ganglia
M2 Heart, hindbrain, smooth muscle
M3 Smooth muscle, glands, brain
M4 Brain (forebrain, striatum)
M5 Brain (substantia nigra), eyeClinical Interventions in Aging 2008:3(3) 505
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is not palpable. The genitourinary examination in women 
should include a pelvic examination to rule out an obstruct-
ing, kinking cystocele, atrophic vaginitis, and urethral diver-
ticulum (palpable mass), and a rectal examination to rule out 
constipation, which can lead to OAB. In the male the size of 
the prostate and assessment for nodules is performed. Neuro-
logic examination should include lumbar and sacral reﬂ  exes 
(anal wink, cremasteric, perianal sensation, bulbocavernosus 
reﬂ  ex, anal sphincter tone) as well as mental status.
The properly collected and processed urinalysis is a 
mainstay in evaluation of OAB. Hematuria, glucosuria, 
proteinuria, and infection can be easily identiﬁ  ed. If the 
urine dip is positive, it is imperative to send the specimen 
for microscopic examination. Hematuria is deﬁ  ned as  3 
red blood cells per high power ﬁ  eld on two separate good 
quality specimens and should prompt comprehensive evalu-
ation for neoplasm (renal mass protocol upper tract imaging, 
cystoscopy, and urine cytology) (Grossﬁ  eld et al 2001a, b). 
Mensturation and vulvovaginal atrophy can contaminate the 
sample in women; recollection or catheterized specimens 
can be helpful.
The importance of obtaining a post void residual urine 
volume in the evaluation of OAB cannot be emphasized 
enough. This procedure can be performed by straight cath-
eterization or bladder scanner in the ofﬁ  ce, or by ultrasound in 
radiology. Incomplete emptying is a common and potentially 
dangerous cause of OAB. It should be screened for in all new 
OAB patients. Incomplete emptying is more likely in those 
with cystocele or prostatic obstruction, neurogenic bladder, 
urinary tract infections, diabetes, and overﬂ  ow (unawares) 
incontinence.
Serum creatinine is helpful in screening for compromised 
renal function. It is recommended (and can be complemented 
by renal ultrasound) in those with incomplete bladder emp-
tying and suspected obstruction by pelvic organ prolapse, 
the prostate, or high-pressure neurogenic voiding dys-
function. Serum glucose should be obtained in those with 
polydypsia/polyuria, if diabetes is suspected.
Behavioral intervention
Intervention on reversible causes of OAB should be 
diagnosis-speciﬁ  c, for example reduction of a cystocele 
and removal of bladder tumor. Once these discreet diagno-
ses have been ruled out, treatment of uncomplicated OAB 
can begin. Behavioral intervention should always include 
patient education. Timed voiding in infrequent voiders or 
in patients with prior central nervous system injury (eg, 
stroke), decreased ﬂ  uid consumption in those with poly-
dypsia or night-time ﬂ  uid intake, caffeine modiﬁ  cation, and 
proper time of diuretic administration are all obvious places 
to start. Biofeedback pelvic ﬂ  oor muscle retraining can be 
used to relax any contributory pelvic ﬂ  oor muscle spasm and 
to educate patients on manipulation of bladder inhibitory 
reﬂ  exes. Unfortunately no peer-reviewed publication speciﬁ  -
cally exists for the use of biofeedback in OAB. However, a 
meta-analysis by Berghmans et al assessing the efﬁ  cacy of 
biofeedback in urge urinary incontinence found that almost 
all studies had positive results in favor of biofeedback but 
better constructed studies were needed to really evaluate its 
efﬁ  cacy (Berghmans et al 2000).
Pharmacologic intervention
There are many medications available for the management of 
uncomplicated OAB. Several agents previously used include 
propantheline, hyoscyamine, and imipramine. Propantheline 
bromide is a non-selective muscarinic receptor antagonist 
with low or varying bioavailability, with less frequent dos-
ing and a larger side-effect burden (Nabi et al 2006). It is 
no longer applied for the treatment of OAB. Hyoscyamine 
sulfate, another muscarinic receptor antagonist, may be useful 
in patients with intermittent symptoms (Malone and Okano 
1999). Its side effect proﬁ  le includes prominent anticholin-
ergic side effects. Imipramine, a tricyclic antidepressant, is 
not routinely recommended for the treatment of OAB, but 
may be useful for stress incontinence or mixed urge – stress 
incontinence due to its effect on bladder neck tone (Wein 
1998). Imipramine is associated with potentially serious CNS 
side effects and cardiotoxicity. More frequently prescribed 
agents for the treatment of OAB are oxybutynin, which has 
a mixed action, and tolterodine. Three additional drugs were 
approved by the US Food and Drug Administration in 2004 
to treat the symptoms of OAB: trospium, which has been in 
use in Europe for the treatment of OAB, darifenacin, and 
solifenacin (Lam and Hilas 2007).
Oxybutynin is one of the less selective muscarinic recep-
tor antagonists (Schaefer 2007). Oxybutynin is available in 3 
different formulations: immediate-release (taken twice daily), 
extended-release (taken once daily), and a transdermal patch 
(applied once every 3.5 days). Each has its own clinical niche. 
For instance, oxybutynin immediate release may be useful as 
a single dose in the evening for patients with nocturia who 
do not have troubling symptoms during the day.
Oxybutynin-ER has a wide dosing range from 5 mg to 
30 mg. This facilitates a dosing regimen that allows for a 
good balance between efﬁ  cacy and tolerability. Oxybutynin 
is also available in a transdermal patch. Due to the fact Clinical Interventions in Aging 2008:3(3) 506
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that transdermal oxybutynin does not undergo ﬁ  rst-pass 
metabolism in the liver, much lower concentrations of 
N-desethyloxybutynin, the active metabolite of oxybutynin, 
are noted. For this reason, in various clinical trials, transder-
mal oxybutynin has been shown to have a relatively low risk 
of side effects; most frequent was application-site reactions 
(Schaefer 2007). Even these may be reduced by the use of 
topical corticosteroid or antihistamine to the site.
Similar to oxybutynin, tolterodine is available in both 
short-acting and long-acting formulations. Both formula-
tions have shown good efﬁ  cacy for the symptoms of OAB in 
large studies (Choo et al 2008). The extended-release form 
is better-tolerated and more effective than the immediate-
release formulation (Choo et al 2008). In one randomized 
controlled study of extended-release tolterodine 4 mg/day 
in patients with urge incontinence and urinary frequency, 
no differences were found for efﬁ  cacy, tolerability, or safety 
between older and younger patients (Wefer et al 2001). In 
another trial, there was a small but statistically signiﬁ  cant 
decrease in the efﬁ  cacy of tolterodine with age (Michel et al 
2002). In another study, The Overactive Bladder: Perfor-
mance of Extended-Release Agents trial, oxybutynin-ER 
and extended-release tolterodine (tolterodine-ER) were 
compared. Reduction in the frequency of incontinence epi-
sodes was similar in the oxybutynin-ER and tolterodine-ER 
groups (Diokno et al 2003). Micturition frequency was more 
reduced in the oxybutynin-ER group than in the tolterodine-
ER group. More importantly, a greater number of partients 
in the oxybutynin-ER group achieved complete continence 
(Diokno et al 2003). In a follow-up study using the same 
data set, central nervous system side effect proﬁ  les of oxy-
butynin-ER and tolterodine-ER were compared (Kay et al 
2006). Adverse events occurred in 9.0% in the oxybutynin-
ER group and 8.3% in the tolterodine-ER treatment groups 
(p   0.8) (Kay et al 2006).
Certain risk proﬁ  les apply to all members of the anti-
cholinergic class. All anticholinergic agents should be used 
with caution and specialty consultation in patients with 
narrow-angle glaucoma, decreased gastrointestinal motility, 
or clinically signiﬁ  cant bladder outﬂ  ow obstruction. Side 
effects of antimuscarinic agents can include changes in blood 
pressure, pulse rate or ECG when beginning treatment. Diz-
ziness and blurred vision are occasionally reported as well. 
The most common side effect is dry mouth (Lam and Hilas 
2007). Constipation and dyspepsia are also reported. Dizzi-
ness and somnolence are common CNS side effects. On the 
whole, side effects are transient and tolerable – although 
constipation is one of the common side effects, the use 
of laxatives and stool softeners is rarely necessary (Anon 
2007). Adverse events or side effects infrequently lead to 
withdrawal of treatment.
Trospium chloride, which is a quaternary ammonium 
compound, has recently been approved by the FDA for 
the treatment of OAB (Staskin et al 2007). It was initially 
provided as a single 20 mg dose for twice-daily use, and has 
more recently been approved in a 60 mg once-daily formu-
lation. Trospium efﬁ  cacy has been shown to be equivalent 
to twice daily oxybutynin-IR with a lower incidence of dry 
mouth (Zinner et al 2004). Trospium also may have a lower 
risk of central nervous system side effects because of its low 
predilection to cross the blood–brain barrier (Guay 2003). 
It also has an added beneﬁ  t of being metabolized by the 
kidneys rather than the cytochrome P450 system, thereby 
having fewer interactions with other medications (Guay 
2003). It may be beneﬁ  cial for patients who are elderly and/or 
receiving multiple medications.
More recent additions for the treatment of OAB are dari-
fenacin and solifenacin, both of which are available in once-
daily formulations. Darifenacin is available in 7.5 mg/day 
and 15 mg/day formulations, with a recommended starting 
dose of 7.5 mg daily. Solifenacin is started at 5 mg once daily 
and dosing may be increased to 10 mg once daily. These 
are M3-selective receptor antagonists which potentially 
may be more bladder-speciﬁ  c with reduced tendency for 
anticholinergic side effects. Agents that are M3-selective 
are associated with relatively high rates of constipation. 
Reported rates of 9.1% and 14.4% have been demonstrated 
for both solifenacin 10 mg daily and darifenacin 7.5 mg daily 
respectively (Anon 2005). Solifenacin should be used with 
caution in patients with reduced hepatic or renal function, 
and darifenacin is not recommended for use in patients with 
severe hepatic impairment. Darfenacin in the 7.5 mg dose 
may be used with caution in patients with moderate hepatic 
impairment, and there are no dosing adjustments for patients 
with mild hepatic impairment. Darifenacin does not require 
dose adjustment for elderly patients, and both medications 
have been shown to have similar safety and efﬁ  cacy between 
older and younger patients (Wagg et al 2006; Chancellor 
and Miguel 2007).
The literature is sparse on head to head trials of the newer 
agents. However, the STAR (solifenacin vs tolterodine mul-
tinational trial) trial compared 4 mg of tolterodine to 5 mg 
then 10 mg of solfenacin (Chapple et al 2005a). At the 10 mg 
dose of solifenacin, there was a 10% greater reduction in the 
number of reported incontinence episodes compared with 
the tolerodine group. Criticism of the study stems from the Clinical Interventions in Aging 2008:3(3) 507
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fact that FDA dosing allowed for an escalated 10 mg dose 
of solifenacin, whereas tolterodine remained at 4 mg. In a 
more recently available subcut analysis of the data comparing 
tolterodine 4 mg ER with solfenacin 5 mg, the authors found 
that within 4 weeks of solifenacin 5 mg therapy, solifenacin 
5 mg was signiﬁ  cantly better than tolterodine ER 4 mg in 
improving incontinence episodes and reducing incontinence 
pad use. At the endpoint of the trial, there was a reduction in 
the number of incontinence episodes from 1.1 in the toltero-
dine arm and 1.6 in the solifenacin arm (p = 0.006) (Chapple 
et al 2005a, 2007a). Differences in efﬁ  cacy continued for the 
duration of the study after the dose increase of solifenacin 
was allowed.
Clinical trials of darifenacin
Darifenacin has been the subject of several randomized clini-
cal trials. Pooled data analysis from 3 studies enrolled over 
a thousand patients (85% female; age range 19–88 years) 
with a minimum 6-month history of overactive bladder 
symptoms including urgency, frequency, and urge inconti-
nence. All participants had a 2-week washout and a 2-week 
placebo run-in prior to the beginning of the trial. Patients 
were randomized to be given either 1) darifenacin 7.5 mg 
or matched placebo or 2) darifenacin 15 mg or matched 
placebo. Outcome data were collected by use of an electronic 
diary. Although there was a noted placebo response, both 
doses of darifenacin were superior to placebo in alleviat-
ing symptoms associated with OAB (Chapple et al 2005b). 
Darifenacin has also been compared with oxybutynin as well 
as a matched placebo. Seventy-six patients (93% female) 
had detrusor overactivity veriﬁ  ed with urodynamics with at 
least 4 urge incontinence episodes per week and a frequency 
of at least 8 micturitions per day. All patients underwent 
a 2-week run-in period prior to 2 weeks of treatment 
in each arm. A paper diary was used to assess outcomes. 
Results revealed a comparable efﬁ  cacy with oxybutynin, in 
comparison to the placebo arm with reduced a side effect 
proﬁ  le (Chapple and Abrams 2005).
Another study looked at the onset of action of darifenacin. 
561 patients (age range 19–88 years; 85% female) with OAB 
symptoms were enrolled for at least 6 months (Haab et al 
2004). After a 2-week washout and a 2-week placebo trial, 
participants were randomized to 3.75 mg darifenacin, 7.5 mg 
darifenacin, 15 mg darifenacin or placebo. Onset of action 
was noted by 2 weeks, although increased beneﬁ  t was seen 
up to 12 weeks in this study (Haab et al 2004).
Another parameter to measure the severity of urinary 
urgency includes warning time. This is the time between 
ﬁ  rst sensation and time of micturition. This in theory rep-
resents the time available for the patient to ﬁ  nd a toilet and 
could reduce social embarrassment. In a study by Chapple 
et al (2007b), 72 patients (51 female) with urinary urgency 
of more than 6 months duration and at least 4 urge episodes 
per day, received either darifenacin 30 mg or placebo. All 
patients again had a 2-week washout period and 2 weeks 
of treatment double blinded. Warning time was recorded 
before and after treatment using electronic event markers. 
The severity of the urgency was recorded on a Likert scale 
from 0 (no urgency) to 3 (severe urgency). After 2 weeks of 
treatment, the warning time increased in the patients taking 
darifenacin by 22.5% compared with a reduction of 18.9% 
in the placebo group (Chapple et al 2007b). This equated to 
a mean increase in warning time of 4.3 min in those taking 
darifenacin (Chapple et al 2007b). This may seem insigniﬁ  -
cantly small but especially in those at home or while in bed 
it provides time to ﬁ  nd a toilet and avoid a socially embar-
rassing event of urge incontinence. Darifenacin’s symptom 
improvement is supported by improvement in quality of 
life scores, as assessed by the King’s Health Questionnaire 
(Nabi et al 2006).
In light of selectivity of muscarinic M3 receptors, dari-
fenacin minimizes the risk of blockade of other muscarinic 
subtypes, eg, M1-mediated cognitive impairment. This is of 
particular importance for older patients who may be more sus-
ceptible to cognitive impairment and central nervous system 
effects. This patient population is at increased risk of cerebral 
exposure from increased permeability of the blood  –  brain 
barrier associated with advancing age, diabetes, Alzheimer’s 
disease, or multiple sclerosis. There is a low incidence of 
cognitive side effects, which is especially beneﬁ  cial for the 
elderly (Nabi et al 2006). In an analysis by Foote et al (2005), 
317 patients aged 65 years or more were evaluated in one 
of three multicenter, randomized, double-blind, and placebo 
controlled studies. All patients had had symptoms of OAB for 
more than 6 months. If patients needed, they had a 2-week 
washout period and a 2-week drug-free/placebo run-in, prior 
to receiving once-daily darifenacin 7.5 mg versus placebo, or 
darifenacin 15 mg versus placebo. At 12 weeks, both doses 
of darifenacin were signiﬁ  cantly superior along all symptoms 
of OAB assessed (Foote et al 2005). This analysis conﬁ  rmed 
the efﬁ  cacy in the elderly population. An important ﬁ  nding 
in this trial was the low incidence of nervous system effects 
(eg, somnolence, dizziness) during darifenacin therapy, 
similar to that with placebo in the present analysis of older 
patients, and also similar to that previously reported for the 
wider patient population.Clinical Interventions in Aging 2008:3(3) 508
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The favorable safety proﬁ  le above is solidiﬁ  ed by data 
showing that darifenacin is not associated with impairment 
of cognitive function, either in older or younger patients. 
This question has not been looked at speciﬁ  cally in any 
other antimuscarinic agent. Kay et al (2006) looked directly 
at cognitive function in 150 healthy subjects older than 
60 years. Design included randomization to darifenacin, 
oxybutynin ER, or placebo in a multicenter, double-blind, 
double-dummy, parallel-group, 3-week study. Doses 
administered were oxybutynin ER 10 mg once daily, 
increasing to 15 mg then 20 mg by week 3 and darifena-
cin 7.5 mg daily in weeks 1 and 2, then 15 mg in week 3. 
The primary end point was accuracy on the Name-Face 
Association Test (delayed recall) at week 3. They found 
darifenacin had no signiﬁ  cant effects on memory versus 
placebo, while oxybutynin ER caused signiﬁ  cant memory 
deterioration, comparable to brain aging of 10 years. This 
study did have some limitations. These included 9 subjects 
who dropped from the darifenacin group, 6 from the oxy-
butynin group and 1 from the placebo group, which may 
have affected results. Also the study did use a higher dose 
of oxybutynin ER, up to 20 mg, while the darifenacin group 
only had 1 dose increase. There may have been differences 
in the group before starting treatment: the darifenacin group 
was slightly younger, has fewer females, and exhibited 
lower starting scores. Lastly, the duration examined was 
only 2 weeks.
The side effect proﬁ  le of darifenacin is associated with 
a higher degree of constipation compared to oxybutynin, 
tolterodine, and trospium. Darifenacin at 7.5 mg has 14.8% 
rate of constipation compared to 21.3% with the 15 mg dose 
as per the product information insert. In addition, darifenicin 
has a 20.2% incidence of dry mouth at 7.5 mg and 35% at the 
15 mg dose. These are important side effect proﬁ  les which 
may guide therapy especially in patients already suffering 
from pre-existing constipation or dry mouth.
Discussion
OAB has a signiﬁ  cant impact on patient health and quality of 
life and is common in elderly patients. Once proper evalua-
tion has ruled out complex causes of OAB, many treatment 
options are available including behavioral and medical ther-
apy. Ideally, therapy should begin with non-pharmacologic 
or behavioral therapy. Medical therapy should be considered 
if necessary. In the majority of the elderly population with 
OAB, a muscarinic receptor antagonist should be able to 
provide substantial relief from the symptoms of OAB, with 
a minimal side effect proﬁ  le. With the variety of agents that 
are available today, and with continuing rigorous clinical 
trials, relief of symptoms can potentially be achieved for 
even the elderly patient population with OAB.
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